No / Breast cancer is one of the most prevalent malignancies worldwide. It consists of a group of tumor cells that have the ability to grow uncontrollably, overcome replicative senescence (tumor progression) and metastasize within the body. Metastases are processes that consist of an array of complex gene dysregulation events. Although these processes are still not fully understood, the dysregulation of a number of key proteins must take place if the tumor cells are to disseminate and metastasize. It is now widely accepted that future effective and innovative treatments of cancer metastasis will have to encompass all the major components of malignant transformation. For this reason, much research is now being carried out into the mechanisms that govern the malignant transformation processes. Recent research has identified key genes involved in the development of metastases, as well as their mechanisms of action. A detailed understanding of the encoded proteins and their interrelationship generates the possibility of developing novel therapeutic approaches. This review will focus on a select group of proteins, often deregulated in breast cancer metastasis, which have shown therapeutic promise, notably, EMT, E-cadherin, Osteopontin, PEA3, Transforming Growth Factor Beta (TGF-β) and Ran.

Yes / Objectives Systemic sclerosis (SSc) is characterised by tissue fibrosis and vasculopathy with defective angiogenesis. Transforming growth factor beta (TGF-β) plays a major role in tissue fibrosis, including downregulation of caveolin-1 (Cav-1); however, its role in defective angiogenesis is less clear. Pigment epithelium-derived factor (PEDF), a major antiangiogenic factor, is abundantly secreted by SSc fibroblasts. Here, we investigated the effect of TGF-β and Cav-1 on PEDF expression and the role of PEDF in the ability of SSc fibroblasts to modulate angiogenesis. Methods P EDF and Cav-1 expression in fibroblasts and endothelial cells were evaluated by means of immunohistochemistry on human and mouse skin biopsies. PEDF and Cav-1 were silenced in cultured SSc and control fibroblasts using lentiviral short-hairpin RNAs. Organotypic fibroblast–endothelial cell cocultures and matrigel assays were employed to assess angiogenesis. Results P EDF is highly expressed in myofibroblasts and reticular fibroblasts with low Cav-1 expression in SSc skin biopsies, and it is induced by TGF-β in vitro. SSc fibroblasts suppress angiogenesis in an organotypic model. This model is reproduced by silencing Cav-1 in normal dermal fibroblasts. Conversely, silencing PEDF in SSc fibroblasts rescues their antiangiogenic phenotype. Consistently, transgenic mice with TGF-β receptor hyperactivation show lower Cav-1 and higher PEDF expression levels in skin biopsies accompanied by reduced blood vessel density. Conclusions O ur data reveal a new pathway by which TGF-β suppresses angiogenesis in SSc, through decreased fibroblast Cav-1 expression and subsequent PEDF secretion. This pathway may present a promising target for new therapeutic interventions in SSc. / NIHR CDF; EULAR ODP

Yes / Aberrant transforming growth factor-β (TGF-β) signaling activation is linked to pulmonary arterial hypertension (PAH). BMPR2 mutations perturb the balance between bone morphogenetic protein (BMP) and TGF-β pathways, leading to vascular remodeling, narrowing of the lumen of pulmonary vasculature, and clinical symptoms. This forum highlights the association of the TGF-β pathway with pathogenesis and therapeutic approaches. / Research carried out at Nasim laboratories is funded by GrowMedtech, the Royal Society, the Commonwealth Scholarship Commission (CSC) and the University of Bradford (UoB). N.S. is funded by the CSC and C.C.N. is partly funded by the UoB.

Le phénotype des chondrocytes peut être modulé par des facteurs de croissance comme par des contraintes mécaniques. Nous avons caractérisé le potentiel chondrogénique de la "Bone Morphogenetic Protein" (BMP)-2 sur des chondrocytes murins primaires amplifiés en culture monocouche sur plastique. Nous avons aussi développé un nouveau modèle d’étude de la mécanotransduction par la compression dynamique de ces cellules incluses en hydrogel d’agarose. Nous avons ainsi confirmé l’implication des voies ERK1/2 et p38 dans ces mécanismes, révélé l’activation de Smad2/3 en réponse à la compression et identifié de nouveaux gènes mécano-sensibles. Par ailleurs, nous avons mis en évidence le rôle des intégrines-bêta-1 dans la rigidité du tissu cartilagineux. Nos résultats complètent la connaissance fondamentale des mécanismes de régulation du phénotype chondrocytaire, mais peuvent également contribuer à l'amélioration des techniques de reconstruction du cartilage dans le domaine de l'ingénierie tissulaire. / Chondrocytes phenotype can be modulated by growth factors as well as mechanical stress. We characterised Bone Morphogenetic Protein (BMP)-2 chondrogenic potential on mouse primary chondrocytes expanded in monolayer on culture plastic. Also, we developed a new model to investigate mechanotransduction by applying dynamic compression on these cells embedded in agarose hydrogel. Hence, we confirmed ERK1/2 and p38 pathways implication in such mechanisms, we revealed Smad2/3 activation in response to compression and we identified new mechanosensitive genes. Besides, we highlighted the role of beta-1-integrins in cartilage stiffness. Our results completed the basic knowledge of regulation mechanisms underlying chondrocytes phenotype, but could also contribute to improve techniques for cartilage reconstruction in the field of tissue engineering.

Procurando compreender o envolvimento da aldosterona (Aldo) na injúria renal, o objetivo deste projeto foi avaliar o efeito do tratamento crônico com Aldo sobre a função renal e a histologia das arteríolas renais, procurando correlacionar os achados com a expressão de genes reguladores do processo de fibrose e apoptose. A Aldo não alterou os parâmetros fisiológicos, PA, ritmo de filtração glomerular (estimado pela depuração plasmática de creatinina), proteinúria e a morfologia das arteríolas corticais. No entanto, aumentou a expressão do RNAm para TGF-β1, PAI-1 e BAX no tecido renal, além da contagem de células TUNEL positivas nos glomérulos. O antagonismo ao receptor MR (pelo uso da espironolactona) aboliu o efeito hormonal somente sobre a expressão do RNAm para BAX e a marcação do DNA degradado (TUNEL), enquanto que o antagonismo ao GR (pelo uso do RU 486) reduziu ou aboliu todos os efeitos da Aldo. Os resultados indicam que a Aldo pode induzir respostas precoces sobre o remodelamento do tecido renal, sem ainda comprometer a função renal ou alterar a PA. Essas respostas foram independentes da sobrecarga de sal e ocorreram por um mecanismo que envolveu os receptores MR e GR. / In order to understand the aldosterone (Aldo) involvement in renal injury, the objective of this project was to evaluate the effect of Aldo chronic treatment on renal function and renal arterioles histology, trying to correlate the findings with the regulatory genes of fibrosis and apoptosis. Aldo did not change the physiological parameters, BP, glomerular filtration rate (estimated by creatinina clearance), proteinuria and cortical arterioles morphology. However, Aldo increased mRNA expression for TGF-β1, PAI-1 and BAX in renal tissue, as well as TUNEL-positive cell count in glomeruli. MR receptor antagonism (by spironolactone) abolished only the hormonal effect on the mRNA expression for BAX and degraded DNA labeling (TUNEL); whereas GR antagonism (by RU 486) reduced or abolished all Aldo effects. The results indicated that Aldo can induce early responses on renal tissue remodeling, without altering renal function or BP. These responses were salt independent and involved MR and GR receptors.

O fator de crescimento transformante beta tipo 1, TGF-β1, é uma proteína extracelular homodimérica secretada por vários tipos celulares, que pode ter ação parácrina ou endócrina. Essa proteína está envolvida em processos celulares de diferenciação, proliferação, mobilidade e formação de matriz extracelular. Além disso, é parte importante dos processos de regeneração tecidual, atuando, de maneira decisiva, no reparo, atraindo macrófagos e fibroblastos para o local da injúria e estimulando a angiogênese. Assim, considerando o papel desse peptídeo no processo regenerativo, o uso de TGF-β1 como proteína terapêutica na área de Bioengenharia Tecidual é bastante promissor. Apesar disso, a venda dessa proteína, para fins terapêuticos, é inexistente no mercado e a proteína recombinante vendida, que só pode ser utilizada em pesquisas científicas, não é produzida nacionalmente e chega a custar R$200.000,00/mg. Nesse contexto, o objetivo do presente trabalho é desenvolver uma metodologia de produção do fator recombinante TGF-β1 em células de ovário de hamster chinês (CHO), visando à obtenção de níveis altos de rendimento, e, futuramente, a transferência da tecnologia de produção para a iniciativa privada, tornando possível seu uso na Medicina Regenerativa, sozinho ou em combinação com outros fatores de crescimento. O cDNA de TGF-β1 foi amplificado a partir de um banco de cDNA humano e clonado no vetor proprietário pNU1 de expressão de mamífero. A construção pNU1/TGF-β1 foi utilizada para transfectar estavelmente células CHO DG44 e uma estratégia de co-amplificação foi utilizada para selecionar células transfectantes com maior número de cópias da sequência correspondente a TGF-β1. Estas culturas foram submetidas ao processo de amplificação gênica com concentrações crescentes de metotrexato. Ensaios de Western Blot e ELISA foram realizados utilizando-se o meio condicionado pelas populações selecionadas e por clones superprodutores. Entre os 41clones obtidos, cinco apresentaram maiores níveis de produção de TGF-β1, entre 1.000 e 2.000 ng/mL. Estes clones foram selecionados para a realização de testes de atividade in vitro utilizando-se células A549, que permitem avaliar a transição epitélio-mesênquima. Um ensaio de cicatrização de feridas em peles do dorso de camundongos foi padronizado e utilizado para avaliar a atividade in vivo do clone que apresentou melhor resultado in vitro. A proteína TGF-β1 foi parcialmente purificada por HPLC em uma coluna de afinidade. Portanto, a proteína TGF-β1 humana recombinante foi produzida, apresentando atividade biológica in vitro e in vivo, sendo capaz de reparar eficientemente feridas cutâneas. Essa iniciativa pode oferecer aos pacientes uma alternativa para o tratamento de lesões teciduais, acelerando a cicatrização de feridas e o reparo de tecidos. / The transforming growth factor beta 1, TGF-β1, is a homodimeric extracellular protein secreted by several cell types, which may have paracrine or endocrine action. This protein is involved in cellular processes of differentiation, proliferation, mobility and formation of extracellular matrix. In addition, it is an important part of the tissue regeneration processes, acting decisively on repair, attracting macrophages and fibroblasts to the site of injury and stimulating angiogenesis. Therefore, considering the role of this peptide in the regenerative process and the use of TGF-β1 as a therapeutic protein in the field of Tissue Bioengineering is very promising. Despite this, the sale of this protein for therapeutic purposes is nonexistent in the market and the recombinant protein available in the market, which can only be used in scientific research, is not produced nationally and the costs are in the order of R$ 200,000.00/mg. In this context, the objective of the present work is to develop a methodology for the production of the TGF-β1 recombinant factor in Chinese hamster ovary (CHO) cells, aiming at obtaining high yields, and, in the future, transfering the production technology to the private initiative, allowing its use in Regenerative Medicine, alone or in combination with other growth factors. The TGF-β1 cDNA was amplified from a human cDNA library and cloned into the proprietary pNU1 mammalian expression vector. The pNU1/TGF-β1 construct was used to stably transfect CHO DG44 cells, and a co-amplification strategy was used to select transfectant cells with the largest number of gene copies. These cultures were subjected to the process of gene amplification with methotrexate. Western Blot and ELISA were used to assay the conditioned medium obtained from the selected cell populations and from overproducing cell clones. Among the 41 clones obtained, five presented higher levels of TGF-β1 production, between 1,000 and 2,000 ng/mL. These clones were selected for in vitro activity testing using A549 cells to evaluate the epithelial-mesenchymal transition. Awound healing assay on mouse dorsal skin was standardized and used to evaluate the in vivo activity of the cell clone which displayed the highest result in vitro. The TGF-β1 protein was partially purified by HPLC on an affinity column. Therefore, the recombinant human TGF-β1 protein was produced and shown to display biological activity both in vitro and in vivo, being able to eficiently repair cutaneous wounds. This initiative may provide patients with an alternative treatment for tissue damage, accelerating wound healing and tissue repair.

Murine Mikrogliakulturen wurden mit Astrozyten-konditioniertem Medium (ACM) in einen deaktivierten Zustand überführt. Dies wurde anhand morphologischer (Grad der Ramifizierung) und immunologischer (Expression von Adhäsionsmolekülen) Parameter verifiziert. Durch den Einsatz von Makrophagen-koloniestimulierenden Faktor (M-CSF), Granulozyten/Makrophagen-koloniestimulierenden Faktor (GM-CSF), transformierenden Wachstumsfaktor beta (TGF-beta) und den gegen sie gerichteten Antikörpern wurde gezeigt, daß alle untersuchten Zytokine in unterschiedlichem Maße an der Deaktivierung der Mikrogliazellen durch ACM beteiligt sind. Außerdem wurde nach Stimulation mit ACM an murinen Mikrogliazellen eine transiente Hochregulation eines Kaliumauswärtsstromes beobachtet Das Auftreten dieses Kalium-stromes nach Inkubation der Mikrogliazellen mit ACM konnte auf die Wirkung von TGF-beta, welches im ACM enthalten ist, zurückgeführt werden. Der durch ACM in deaktivierter Mikroglia induzierte Kaliumkanal entsprach in seinen kinetischen und pharma-kologischen Eigenschaften am ehesten dem klonierten Kanal Kv1.3. Die Kv1.3 Expression durch TGF-beta oder ACM war durch den unspezifischen Proteinkinaseinhibitor H7 unterdrückbar. Diese Ergebnisse zeigen, daß die Expression des Kv1.3 Kanals nicht, wie bisher angenommen, ein Indikator für aktivierte Mikroglia ist. / Murine microglial cultures were deactivated with astrocyte-conditioned medium (ACM). The deactivation process was verified measuring morphological (ramification index) and immunological (expression level of adhesion molecules) parameters. By using macrophage-colony stimulating factor (M-CSF), granulocyte/macrophage-colony stimulating factor (GM-CSF), transforming growth factor beta (TGF-beta) and their corresponding antibodies it was shown, that to a different extent all of these cytokines influence the deactivation process of microglial cells by ACM. ACM treatment of microglial cultures also lead to a transient upregulation of a delayed potassium outward current. This upregulation was due to the impact of TGF-beta contained in ACM. The ACM induced potassium channel resembled in its kinetic and pharmacological properties the cloned Kv1.3 channel. Expression of Kv1.3 in microglial cells by TGF-beta or ACM was inhibited by the unspecific protein kinase inhibitor H7. These results show, that expression of Kv1.3 channels is not a special feature of activated microglia, which has been proposed in recent publications.

Les cellules souches de l’épiderme interfolliculaire humain, appelées cellules souches kératinocytaires (CSK), assurent l’homéostasie et le renouvellement du tissu durant toute la vie d’un individu grâce à leur importante capacité d’autorenouvellement. Ma thèse de doctorat a porté sur l’étude des effecteurs moléculaires impliqués dans la balance entre prolifération et quiescence dans un modèle in vitro de CSK, isolées de manière clonale et définies par le terme holoclone. Je me suis tout d’abord intéressée à la réponse des holoclones à l’effet d’un régulateur important de la prolifération et de la quiescence des cellules souches adultes : le facteur de croissance TGF β1. Mon travail s’est ensuite focalisé sur l’étude d’un gène agissant en aval de la voie de signalisation TGF β, le facteur de transcription Klf4, et dont le rôle dans la biologie des cellules souches adultes reste largement méconnu. Klf4 est en effet surtout décrit pour son rôle dans la reprogrammation des cellules somatiques en cellules iPS. Le maintien de la sensibilité des holoclones aux signaux inhibiteurs de la croissance constitue un gage de la normalité des CSK. Notre étude de la réponse des holoclones à l’effet antiprolifératif du TGF β1 montre que les holoclones, dotés d’un fort potentiel de croissance, caractéristique des CSK, conservent leur sensibilité à l’effet du TGF β1. Ces résultats nous ont permis de valider les holoclones comme constituant un modèle pertinent pour caractériser la biologie normale des CSK et décrypter les contrôles moléculaires de l’état souche. Le modèle des holoclones a été exploité dans le cadre d’une approche de génomique fonctionnelle visant à déterminer le rôle du facteur de transcription Klf4 dans les CSK. L’utilisation de vecteurs lentiviraux exprimant un shARN dirigé contre l’ARNm de Klf4 nous a permis d’étudier l’impact d’une modulation fine du niveau d’expression de Klf4 sur les propriétés des holoclones. La répression transcriptionelle de Klf4, d’environ un facteur 2, favorise de manière significative l’expansion du compartiment clonogénique au sein des holoclones. Ce gain de fonction concerne à la fois les potentiels de croissance et de reconstruction épidermique des holoclones. Un aspect important de ce travail a concerné la recherche des réseaux moléculaires régulés par Klf4 dans les holoclones. Une analyse du transcriptome nous a permis de montrer que Klf4 participe au contrôle des mécanismes de cycle cellulaire et de différenciation. Klf4 interviendrait également dans la régulation des voies de signalisation TGF β/BMP et Wnt, connues pour exercer des rôles clés dans la biologie des cellules souches. Klf4 constituerait donc un censeur de l’activité du compartiment immature dans l’épiderme interfolliculaire. Il participerait aux mécanismes de régulation du cycle cellulaire et serait susceptible d’intervenir dans le contrôle de l’autorenouvellement du compartiment souche. / Stem cells present within the human interfollicular epidermis, which are defined as keratinocytes stem cells (KSC), ensure the homeostasis and renewal of the tissue throughout the whole individual life. These functions are related to their important self-renewal capacity. My PhD project was focused on the knowledge of the molecular effectors involved in the control of the balance between proliferation and quiescence in KSC. This scientific question was investigated in an in vitro model of KSC which were clonally derived and characterized as holoclones. Holoclones are controlled by mitogenic growth factors and also by antiproliferative signals. One of these regulators is the growth factor TGF β1 which plays an important role in the control of quiescence and cell proliferation within several adult stem cell systems. In the context of growth inhibition by TGF β1, I have studied the role of a downstream gene of the TGF β pathway, the transcription factor Klf4, whose role in adult stem cell biology remains unclear. In fact, Klf4 is mostly described for its involvement in the reprogramming process of somatic cells into iPS cells. The maintenance of holoclone sensitivity to cell growth inhibitors is a critical parameter of KSC normal physiology. Holoclones possess an extensive growth capacity, which is characteristic of KSC. Despite this high proliferation rate, holoclones are still responsive to the antiproliferative effect of TGF β1. These results allowed us to validate the use of holoclone as a relevant model of non-transformed KSC suitable for the characterization of the role of candidate stemness genes in KSC biology, such as Klf4. The holoclone model was exploited to perform a functional genomic approach to investigate the role of Klf4 in KSC. We have developed a shRNA-based gene knock-down method using lentiviral vectors to assess the impact of Klf4 down-modulation on holoclone functional properties. Our results show that Klf4 down modulation controls the expansion of the clonogenic compartment present within holoclone progeny. This gain-of-function, which is maintained at the long term level, leads to an increase in holoclone 3D epidermis reconstruction capacity. A major point of this project was to elucidate the molecular networks controlled by Klf4 in holoclones. Microarray data show that Klf4 regulates the expression of several genes related to pathways involved in the control of stem cell fate. In particular, we identified many transcripts related to TGF β/BMP and Wnt signallings. Interestingly, the majority of the modulated transcripts are involved in the regulation of cell cycle and in keratinocyte differentiation process. All together these results suggest a critical role Klf4 as a stemness censor of the most immature compartment activity. Klf4 is likely to be involved in cell cycle regulation of KSC compartment and in the control of KSC self-renewal process.

L’infection chronique par le virus de l’hépatite C (VHC) conduit au développement de la fibrose et de la cirrhose qui risque d’évoluer vers le carcinome hépatocellulaire (CHC). La protéine de capside du VHC interagit avec de nombreuses protéines de l’hôte et en particulier avec Smad3, protéine majeure de la voie de signalisation du transforming growth factor beta (TGF-Β). Mon travail de thèse consistait à étudier les conséquences biologiques de l’interaction entre la protéine de capside avec la voie de signalisation du TGF-Β. Le VHC présente une grande variabilité génétique et des travaux du laboratoire ont montré l’existence de séquences différentes de protéines de capside du virus entre les régions tumorales (cT) et cirrhotiques (cNT) d’un même sujet. Nous avons montré que ces différentes protéines de capside exprimées dans des hépatocytes orientent les réponses biologiques du TGF-Β vers la promotion tumorale en diminuant l’apoptose et en augmentant la transition épithelio-Mésenchymateuse (TEM) en particulier le variant cT. Cet effet est attribué à la capacité de la protéine de capside de diminuer l’activité transcriptionnelle de Smad3. De plus, les variants de la protéine de capside activent le TGF-Β latent via l’augmentation de l’expression de la trombospondine. L’un des marqueurs classiquement exprimé au cours d’une TEM est l’alpha-Actine musculaire lisse (αSMA). Nous avons montré qu’une autre isoforme, la γSMA, était polymérisée dans les cellules hépatiques développant une TEM. L’expression de γSMA a été retrouvée sur des coupes de CHC et a pu être significativement corrélée à la fois avec des marqueurs de la TEM, des marqueurs progéniteurs et avec l’agressivité de la tumeur.Ce travail apporte une meilleure compréhension du rôle de la protéine de capside dans la fibrose hépatique liée à l’infection virale. En effet, la protéine de capside du VHC agit à la fois de façon autocrine dans les hépatocytes en modulant les réponses du TGF-Β vers la promotion tumorale et de façon paracrine, en affectant l’activation des cellules étoilées en myofibroblastes par le TGF-Β activé. / Chronic HCV infection) may progress to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCV core binds several cellular proteins and in particular Smad3, a major protein of transforming growth factor beta (TGF-Β) signalling.. The aim of this study was to determine the implication of HCV core protein in TGF-Β responses. High genetic variability is a characteristic of HCV and it was previously shown that HCV core protein isolated from tumour (cT) or adjacent non-Tumour (cNT) livers displayed different sequences. Both were able to shift TGF-B responses from tumour suppressor to tumour promotor by decreasing hepatocyte apoptosis and increasing epithelial-Mesenchymal transition (EMT). Core cT was more potent than core cNT to promote this effect that was mainly attributed to the capacity of HCV core to alleviate Smad3 activity. Moreover, HCV core protein activated the latent form of TGF-Β through increased thrombospondin expression. It is commonly accepted that αSMA (alpha smooth muscle actin) is a hallmark of EMT. In the current study another SMA isoform, γSMA was found to be polymerized during hepatocyte EMT. γSMA was expressed in HCC tissues and correlated with EMT, stem cell and aggressiveness markers. In conclusion, this work contributed to a better understanding of the HCV core role in hepatitis fibrosis and HCC related to HCV. Indeed, HCV core might act both as an autocrine and paracrine way by modulating TGF-Β responses within hepatocytes and by activating hepatic stellate cells in stromal environment through its capacity to activate TGF-Β.

La myélofibrose primitive (MFP) est un néoplasme myéloprolifératif chromosome Philadelphie négatif rare, mais de pronostic sévère. Elle se caractérise par une prolifération clonale et une mobilisation des cellules souches et progéniteurs hématopoïétiques (CSH/PH) de la moelle osseuse vers la rate et le foie. Cette anomalie de l’hématopoïèse est associée à une pathologie du stroma (myélofibrose, ostéosclérose et néoangiogenèse). L’existence d’anomalies moléculaires de la CSH/PH telles que les mutations de Jak2, Mpl, TET2 ou CALR ne permet pas à elle seule d’expliquer la physiopathologie de la maladie. Les résultats obtenus dans le laboratoire suggèrent que le microenvironnement médullaire au sein des niches hématopoïétiques et en particulier les cellules stromales mésenchymateuses (CSM), participe vraisemblablement à cette dérégulation de l’hématopoïèse, favorisant le développement du clone pathologique. Cependant, aucune preuve tangible d’une altération des CSM médullaires n’a été jusqu’à présent apportée.Dans ce travail, nous avons isolé les CSM de la moelle de patients atteints de MFP et réalisé une caractérisation « complète » de ces cellules : prolifération, phénotype, soutien de l’hématopoïèse, sécrétome, transcriptome, miRNome et capacités de différenciation. Nos résultats ont permis de dégager un faisceau d’arguments en faveur d’une dérégulation de leur différenciation ostéoblastique (DOB). (i) Les cytokines BMP2, RANTES, PDGF, TGF-β1, VEGF et Il-6 sont significativement produites en plus grande quantité par ces cellules. (ii) L’étude du transcriptome a révélé une expression significativement différente d’un ensemble de gènes impliqués dans la DOB tels que RUNX2, DLX5, TWIST1 et NOGGIN. (iii) De nombreux micro-ARN, dont certains sont connus pour être impliqués dans la DOB comme miR-210 ou dans le nichage des cellules souches hématopoïétiques comme miR-34a, sont dérégulés à l’état basal et au cours de cette DOB. (iv) Enfin, l’étude de leurs capacités de différenciation ostéoblastique in vitro et in vivo chez la souris immunodéprimée est en faveur d’une augmentation de ces capacités. Nous avons étudié l’impact du TGF- β1 dans cette DOB. Nous avons mis en évidence que les CSM de malades présentent un état basal d'activation de la voie de signalisation pSmad significativement augmenté, confirmant l’expression endogène de TGF-β1. En utilisant des inhibiteurs spécifiques du récepteur de type I au TGF- β, nous avons montré l’implication de cette cytokine dans les altérations de la DOB. En conclusion, notre travail montre pour la première fois que les CSM des malades de MFP sont anormales et ce indépendamment de la stimulation par le clone hématopoïétique pathologique, suggérant la présence d'anomalies constitutives ou acquises. Ces anomalies impliquent deux acteurs majeurs de la pathologie : le TGF-β1 et l'ostéogenèse. / Primary myelofibrosis (PMF) is a Philadelphia-negative myeloproliferative neoplasm, rare but associated with a poor prognosis. Its features are a clonal proliferation and an egress of hematopoietic stem cells (HSC) from bone marrow to spleen. These abnormalities of hematopoiesis are in relation with a pathological stroma (myelofibrosis, osteosclerosis and neoangiogenesis). Molecular abnormalities present in HSC partially explain the physiopathology of the disease. Results from our lab suggest that the bone marrow micro-environnement, especially mesenchymal stromal cells (MSC), are involved in the deregulation of hematopoiesis, promoting the clonal cells. However, there is no strong evidence of bone marrow MSC alterations reported for now.In our study, we isolated MSC from bone marrow of patients suffering from PMF and performed a broad characterization: proliferation, phenotype, hematopoiesis supporting capacities, secretome, transcriptome and miRNome analysis. Our results highlight arguments in favor of a deregulation of their osteogenic capacities. (i) Cytokines NMP2, RANTES, PDGF, TGF-β1, VEGF and Il-6 were significantly overproduced by MSCs. (ii) Transcriptome analysis revealed a specific signature involving genes participating in osteogenic differentiation such as RUNX2, DLX5, TWIST1 and NOGGIN. (iii) Many micro-RNAs, some know to be involved in osteogenic differentiation regulation, as mir-34a, are deregulated in MSCs and in MSC-derived osteoblasts. (iv) Finally, study of their osteogenic potency in vitro and in vivo in nude mice showed an increasing of their osteogenic potency. We studied the impact of TGF-β1 in this process and showed that PMF MSCs showed a basal expression of Smad pathway significantly increased as compared to control. Using specific inhibitor of TGF-β1 receptor, we demonstrated the implication of this cytokine in the osteogenic impairment.To summarize, our work shows for the first time that MSCs from PMF patients are abnormal, independently from stimulation by clonal cells, suggesting intrinsic abnormalities. These abnormalities involve two main factor of the disease: TGF-β1 and osteogenesis.